medical need. Estimates indicate an incidence of ap proximately 750,000 strokes per year in the United States, with prevalence of about 4 million survivors, who are at high risk of a secondary cardiovascular event. The stroke therapies market is estimated at $1 billion with an annual health care cost of $30 to $50 billion (this in cludes half of all patients hospitalized for acute neuro logic disease). Increased prevalence of stroke is expected by the year 2050 with more than 1 million strokes per year expected in the United States. (Stephenson, 1998; Fisher and Bogousslavsky, 1998; Pancioli et aI., 1998) .
Stroke is most commonly the outcome of an obstruc tion of blood flow in a major cerebral vessel (usually the middle cerebral artery), which, if not resolved within a short period of time, will lead to a core of severely isch emic brain tissue that may not be salvaged. However, the ultimate size of the brain infarct also depends on the penumbra, a zone of tissue around the core of the infarct where neuronal electrophysiology is not compromised 820 F. C. BARONE AND G. Z. FEUERSTEIN and blood flow is still maintained above a neuronal dis abling level (i.e., the critical 20% to 25% of normal blood flow). If blood flow in this penumbral zone further decreases below this critical level and/or energy require ments are exceeded, the infarct zone will inevitably ex pand. Thus, blood flow levels are the driving force in determining the size of the ultimate infarct by providing the conditions essential for maintenance of cellular en ergy hemostasis. Figure 1 provides a schematic diagram outlining some of the known events involved in neuronal death after ischemic stroke. Decreased blood flow leads to a reduction in phosphocreatinine and ATP (especially the latter), and if ischemia is prolonged, the energy depletion will be sufficient to lead to severe impairment of cellular function by disruption of ATP-dependent pro cesses.
The disruption of ionic gradients across excitable (neuronal) and nonexcitable (glial) membranes owing to loss of A TP is characterized by efflux of K+ from the cells, cellular depolarization, and influx of Na+, CC and Ca2+ into the cells (Siesjo, 1992a,b) . Of these events, the increase in extracellular K+, along with a decrease in pH, precedes the other ionic changes. In this phase, ATP stores are rapidly depleted and ultimately result in marked changes in ion conductance. It is postulated that 
that occur in thromboembolic ischemic stroke. Ischemic stroke reduces energy availability and therefore membrane ionic primes fail rapidly. The increase in extracellular potassium can reach levels sufficient to release excitotoxic neurotransmitters (e.g., glutamate and aspartate) to stimulate sodium/calcium channels coupled to glutamate receptors that can facilitate de veloping cytotoxic edema. The significant influx of calcium through calcium channels increase free cytosolic calcium that causes mitochondrial calcium overload, cessation of already compromised ATP production, and extensive breakdown of cel lular phospholipids, proteins, and nucleic acids owing to Ca2+ activation of phospholipases, proteases, and endonucleases. Free radicals are produced in the process and contribute to mem brane lipid peroxidation, protein and nuclear DNA toxic changes, and cellular injury (Le., necrosis and/or apoptosis).
J Cereb Blood Flow Metab, Vol. 19, No.8, 1999 the increase in K+ can reach levels sufficient to release neurotransmitters such as glutamate, which in tum will stimulate Na+/Ca2+ channels coupled to the NMDA re ceptor; these events will further lead to Na+, Cl-, and H20 accumulation, cell swelling, and cytotoxic edema.
In parallel, extracellular Ca2+ enters into cells through both voltage-operated and receptor-operated calcium channels, leading to elevated free cytosolic Ca2+, which causes mitochondrial calcium overload and further com promise of ATP production. Transient extracellular K+ induced depolarizations can also contribute to the expan sion of the neuronal lesion. Peri-infarct depolarization produces disruption of ionic gradients and transmitter release, with the associated accumulation of free Ca2+ in the cells leading to rapid and extensive breakdown of phospholipids, proteins, and nucleic acids by activation of calcium-dependent phospholipases, proteases, and en donucleases. Depolarization causes an increase in intra cellular calcium and an increase in extracellular gluta mate. Glutamate, an excitatory neurotransmitter impli cated in ischemic neuronal damage, results in excitotoxicity in which excessive extracellular glutamate kills neurons through an increase in intracellular calcium.
Glutamate-mediated excitotoxicity is thought to occur because of excessive activation of AMPA and NMDA synaptic glutamate receptors. The NMDA receptor chan nel conducts Na+ and calcium as do some AMPA recep tor channels. AMPA receptors also control the initial membrane depolarization caused by glutamate, and af fect the opening of the NMDA receptors. AMPA and NMDA receptors are two targets currently being pursued pharmacologically.
Accumulation of products such as free fatty acids (es pecially the unsaturated) that are metabolized to toxic lipid peroxides (via lipid peroxidation) further contribute to structural and functional perturbations of the mem brane and cell function. Free radicals (a group of highly reactive oxygen species) are generated during ischemia and cause considerable damage to lipids, DNA, and pro teins, and contribute to the process of neuronal death.
Free radicals also contribute to the breakdown of the blood-brain barr ier and brain edema. Levels of free radi cal scavenging enzymes (e.g., superoxide dismutase) de crease during ischemia and nitric oxide levels are el evated. Nitric oxide generated primarily by neuronal and inducible nitric oxide synthases promote neuronal dam age after ischemia. Activation of cytosolic proteases by the increased intracellular Ca2+ can result in the direct disassembly of the cellular microtubule system and pro teolytic degradation of structural and functional protein.
A specific event associated with protease activation, the conversion of xanthine dehydrogenase to xanthine oxi dase, bears directly on cellular formation of toxic struc tures (Barone et. aI., 1998; Koroshetz and Moskowitz, 1996; Ryan et aI., 1997; Albers, 1997; Wahlgren, 1997) .
TARGETING CYTOKINES IN BRAIN INJURY INFLAMMATION
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In summary, reduction in cerebral blood flow depletes energy to sufficiently low levels that perturb cellular ionic homeostasis. A key consequence is an increase in intracellular calcium. This has been the main, consistent event focused on by scientists during the past three de cades of stroke research. Increased intracellular calcium is responsible for the release of neurotransmitters and the activation of many enzymes. Glutamate has been focused on as the excitotoxic neurotransmitter released by the ischemia-induced depolarization. The consequences of endonucleases activation may include apoptosis (pro grammed cell death) (Li et ai., 1998b; Morrison et ai., 1998; MacManus and Linnik, 1997) as DNA damage is well documented in brain ischemia.
PREVIOUS THERAPEUTIC APPROACHES HAVE BEEN UNSUCCESSFUL
Basic research conducted in the areas cited above yielded numerous pharmacologic agents such as ' calcium channel blockers and a variety of glutamate receptor an tagonists (i.e., targeting various glutamate and gluta mate-associated receptors). Approaches targeting oxygen free radicals have also been pursued. Although develop ment of compounds based on all these mechanisms con tinues, no calcium channel blocker, oxygen radical scav enger, or glutamate receptor antagonists successfully completed phase III clinical development. One reason for the difficulties in demonstrating thera peutic benefits with these compounds is that changes associated with these targets occur very soon after stroke (Fig. 2) . Calcium changes happen within seconds to min utes after the ischemia insult. In fact, calcium levels maximize in about 2 minutes. Glutamate release has been demonstrated to be at maximum after 20 to 40 minutes, and most of the damage associated with its excitoxicity may occur within the first 60 minutes. Oxygen free radi cals are very short-lived. Thus by the time the patient is available for treatment in the emergency room these mechanisms of damage might be largely exhausted.
THE BRAIN INFLAMMATORY RESPONSE TO INJURY: A THERAPEUTIC OPPORTUNITY
Direct trauma, deprivation of oxygen and nutrients (ischemia), neurotoxicity, viral infection, or immuno logical challenge produce a well-defined response of gliosis (Perry and Gordon, 199 1) . The activation, prolif eration, and hypertrophy of cells derived from the mono nuclear phagocytic system (e.g., macrophages and mi croglia) are the hallmark of this reaction. Originally, this response was thought to mediate repair by restoring blood supply, reestablishing the integrity of the blood brain barrier, and promoting general homeostasis at the site of injury (Norton et ai., 1992; O ' Callaghan, 199 1; Lindsay, 1986; Eng, 1988; Giulian et ai., 1988) .
Since cytokines activate glial cells (Eng, 1988) , which then produce cytokines (Giulian et ai., 1986; Lieberman et ai., 1989 Lieberman et ai., , 1992 Sawada et ai., 1989) , a close relation ship appears to exist between inflammation, cytokine production, and gliosis. Indeed, gliosis can be induced by tumor necrosis factor-a (TNF-a), interleukin (IL)-1 f3, and interferon a (Balasingam et aI., 1994; Selmaj et aI., 1990; Sawada et ai., 1989) . Further implications for the potential central involvement of cytokines in brain in flammation have been derived from studies on the local ization of TNF-a and IL-l f3 after surgical injury to the hippocampus in rats (Tchelingerian et aI., 1993) , in mul tiple sclerotic plaques in human brain (Hofman et ai., 1989) , and in human head injury (Griffin et ai., 1994) .
Several cell types within the brain are able to secrete cytokines: microglia, astrocytes, endothelial cells, and neurons. In addition, there is also evidence to support the involvement of peripherally derived cytokines in brain inflammation. The blood-brain barrier is permeable to cells of the immune lineage (Tsuchihashi et aI., 198 1; Giulian et aI., 1989) . Peripherally derived mononuclear phagocytes, T -lymphocytes, natural killer cells, and polymorphonuclear leukocytes (PMNs), which produce and secrete cytokines, can all contribute to central ner vous system (CNS) inflammation and gliosis. In support of this, irradiation of the bone marrow or treatment in vivo with colchicine, attenuate gliosis, wound repair, neovascularization, and generalized inflammation (Giu lian et ai., 1989) .
The inflammatory response to brain injury after focal stroke has been studied systematically by several inves tigators. The early accumulation of neutrophils in isch emic brain damage has been clearly shown based on histopathological (Garcia and Kamijyo, 1974; Hallen beck et aI., 1986; Chen et ai., 1992; Dereski et ai., 1992; Clark et ai., 1993 Clark et ai., , 1994 Zhang et ai., 1994a; Ritter et ai., 1998 ), biochemical (Barone et aI., 199 1, 1992b , and I I l in-labeled leukocyte studies (Pozzilli et ai., 1985; Dutka et aI., 1989) . Ameboid microglia, a form of acti vated microglia, can be identified within 2 hours of isch emia. Unlike normal brain microvessels that are clear of inflammatory cell, brain microvessels from ischemic zones are filled with leukocytes and a significant zone of edema surrounds them (see Fig. 3 , rat focal stroke). Many of the leukocytes, primarily neutrophils, found in vessels within ischemic tissue are adherent to the endo thelium, a situation not normally observed in normal brain microvessels. Some of these neutrophils migrate outside the vascular walls into the focal ischemic cortex. Brain injury is associated with the expression of inflam matory mediators, e.g., inflammatory cytokines (IL-l and TNF-a) and chemokine (IL-8 for neutrophils, MCP-1 for monocytes, RANTES, L TB4, IP-IO), while up-regulation of adhesion receptors (ICAM-l, selectins) The inflammatory response to tissue injury occurs after these initial changes but contributes to the ongoing evolution of tis sue injury. Immediate early re sponse genes are expressed within 2 hours, and then in flammatory cytokines (e.g., in terleukin (IL)-1 (3 and tumor ne crosis factor (TNF)-rr), chemo kines and adhesion molecules (e. g. , ICAM-1) are expressed and drive the inflammatory re sponse. Leukocytes accumulate within vessels and tissues (e.g., initially neutrophils and then later monocytes/macrophages). Tissue remodeling factors (e.g., transforming growth factor-(3) are expressed later and are associated with resolution/healing of infarcted tissue. The shaded area indicates the time window post-stroke where one might expect acute intervention to be successful. After 3 hours, tissue plasminogen activator (the only approved therapy for strokes) cannot be administered for thrombolysis because of increased hemorrhage liability. Typically, patients are available for therapeutic intervention beyond 3 hours after stroke onset.
Normal Flow
No Contact Rolling Finn Adhesion Diapedesis support leukocyte adherence to the endothelium (Feuer stein et aI., 1998). Tumor necrosis factor-a and IL-l � predispose or "prime" endothelium for cellular adher ence. Additionally, adhesion molecules such as CD 111 CD 18 integrins are also thought to be pivotal in this inflammatory process (Pober and Cotran, 1990) . The im portance of leukocyte infiltration in the pathogenesis of brain injury has been reviewed previously Feuerstein et aI., 1998; Kochanek and Hallenbeck, 1992; Kogure et aI., 1996; Stoll et aI., 1998) . This in flammatory reaction not only contributes to lipid membrane peroxidation, but also exacerbates the degree of tissue injury caused by the rheologic effects of "sticky" leukocytes in the blood vessels (i.e., an inter ference with normal microvascular perfusion attributable to vascular plugging in an already compromised isch emic tissue bed), and also caused by the release of cy totoxic products from these activated leukocytes (i.e., by FIG. 3 . Histologic and schematic representations of changes in leukocyte behavior in the brain microvessels after focal ischemia. Shortly (within 1 to 6 hours) after experimental stroke, many of the leukocytes, primarily neutrophils, in the ischemic tissue ves sels are adherent to the post-capillary venuole and capillary walls. This can modify and exacerbate the decreased blood flow occurring in the already ischemic brain. Then, these neutrophils can find their way outside the vascular walls into the focal isch emic cortex over the next 6 to 24 hours. Macrophages move into the brain later (i. e. , over 1 to 5 days) and significantly accumulate in the infarcted brain. These changes in leukocyte behavior are mediated by increased brain inflammatory cytokine, adhesion molecule(s), and chemokine expression in the ischemic/injured brain.
generation and release of oxygen radicals and cytotoxic products that are cytodestructive to the already compro mised tissue) (Kochanek and Hallenbeck, 1992; Kogure et aI., 1996; Hallenbeck and Dutka, 1990; Del Zoppo et aI., 199 1; Grau et aI., 1992; Zhang et aI., 1994b; Schmid Schonbein, 1987) . The exact nature of the signaling mechanisms in brain inflammation still remains to be elucidated but undoubtedly involves TNF-a and IL-I [1, chemotactic cytokines (e.g., chemokines such as IL-8), as well as the expression of adhesion molecules and pro teinases that together promote both recruited cell adher ence and infiltration, and enhanced permeability of brain endothelium. For example, for a neutrophil to adhere to the endothelium and then migrate unidirectionally into the tissue, adhesion molecules have to be up-regulated.
To upregulate adhesion molecule expression, injury must up-regulate specific cytokines, such as TNF-a and IL-1�. This has to happen very rapidly, and proteins also have to be rapidly translated. In addition, when those cytokines are expressed and translated, they have to up regulate adhesion molecules and produce chemokines that will induce chemoattraction to drive neutrophils into the tissue. In the remainder of this discussion, the role of TNF-a and IL-l [1 in traumatic and ischemic brain injury and the cooperative actions of chemokines and adhesion mol ecules in this process will be highlighted. Furthermore, the cascade of new gene expression that unfolds after focal stroke, which are key to the inflammatory reaction, will be explained, and the complex nature of protective and destructive gene products on histologic and func tional outcomes after stroke will be addressed. Finally, novel approaches to block cytokines and brain inflam mation will be presented.
ROLES OF TNF-a IN TRAUMATIC BRAIN TRAUMA AND STROKE
Tumor necrosis factor-a is a pleotrophic cytokine re leased by many cell types on diverse stimulation. Tumor necrosis factor-a exerts a multiple array of biological activities including stimulation of acute phase protein secretion and vascular permeability (Tracey and Cerami, 1993) . Tumor necrosis factor-a and its receptors are present in the CNS (Smith and Baglioni, 1992) . In addi tion, several clinical studies have shown a distinct rela tionship between elevated levels of cytokines, including TNF-a, neurodegenerative disorders, and brain injury (for reviews, see Feuerstein et aI., 1998; Barone, 1999) .
Elevated TNF-a has been repeatedly shown in various experimental models of brain injury. Systemic kainic acid administration induces TNF-a mRNA levels in ce rebral cortex, hippocampus and hypothalamus 2 to 4 hours later (Minami et aI., 199 1) . Systemic or intracere broventricular administration of lipopdysaccharide endotoxin has also been shown to increase brain TNF-a levels as determined by bioassay (Siren et aI., 1992) , while injection of the excitotoxin ibotenic acid into the rat pos terior hypothalamic region increased hippocampal TNF-a 2 weeks later (Alvarez et aI., 1994) . In a model of closed head injury, Shohami et aI. (1994) reported an early increase in TNF-a peptide at the site of the focal insult. Also, in rat traumatic head injury, TNF-a mRNA and protein levels are rapidly elevated (Fan et aI., 1996; Taupin et aI., 1993) . Furthermore, in mice challenged with particles of charcoal injected into the hippocampus, an increase in striatal levels of TNF-a mRNA was ob served (Tchelingerian et aI., 1993) . Elevated serum TNF-a was also observed after severe head injury in humans (Goodman et aI., 1990) .
Elevated expression of TNF-a mRNA and protein oc curs shortly (1 to 3 hours) after middle cerebral artery occlusion (MCAO) in rats (Liu et aI., 1994; Wang et aI., 1994b) . Ischemic cortex levels of TNF-a mRNA were elevated as early as 1 hour after occlusion (i.e., before significant influx PMN), peaked at 12 hours, and per sisted for approximately 5 days. The early expression of TNF-a mRNA preceding leukocyte infiltration suggests that TNF-a may be involved in this response. Double label immunofluorescence studies localized the de novo synthesized TNF-a to neurons but not astroglia. At 5 days after the ischemic insult, neuron ally associated TNF-a was diminished, and TNF-a immunoreactivity was localized in the inflammatory cells. The significance of TNF-a expression in the brain was studied by micro injection of TNF-a into the rat cortex; TNF-a-induced leukocyte adhesion to the capillary endothelium, but no evidence for neurotoxicity at the site of injection was found. Buttini et a1. (1996) identified a rapid upregula tion of TNF-a mRNA and protein in activated microglia and macrophages after focal stroke, again suggesting that TNF-a is part of an intrinsic inflammatory reaction of the brain following ischemia. Tumor necrosis factor-a may exert a primary effect on microvascular inflamma tory response as reflected by TNF-a-induced neutrophil adhesion to brain capillary endothelium (Liu et aI., 1994) . Furthermore, intracerebroventricular injection of TNF-a 24 hours before MCAO exacerbates the isch emia-induced tissue injury (Barone et aI., 1997a) . This effect was reversed by ventricular administration of anti TNF-a monoclonal antibody in the contralateral ven tricle. Further evidence for the involvement of TNF-a in stroke-induced injury is supported by findings that spon taneously hypertensive rats that are stroke prone have higher levels of TNF-a production in the brain as com pared with normotensive rats (Siren et aI., 1992) . These data suggest that TNF-a may prime the brain for subse quent damage by activating capillary endothelium to a pro-adhesive state, possibly through the up-regUlation of surface endothelial adhesion molecules (see below).
INTERLEUKIN-lP IN BRAIN TRAUMA AND STROKE
Accumulating evidence shows that IL-113 can be pro duced in the CNS from various cellular elements includ ing microglia, astrocytes, neurons, and endothelium. Like TNF-a, IL-113 has many pro-inflammatory proper ties, and receptors for this cytokine have been shown in the CNS (Rothwell, 199 1; Dinarello, 1988; Takao et aI., 1990) . Increase in IL-113 mRNA expression has been shown to occur after several types of injury to the brain including kainate excitotoxicity (Minami et aI., 199 1) and lipopdysaccharide endotoxin (Ban et aI., 1992; Buttini and Boddeki, 1995) . Furthermore, mechanical damage after implantation of a microdialysis probe has been shown to induce expression of IL-113 (W oodroofe et aI., 199 1). After fluid percussion brain trauma in the rat, a rapid increase in IL-113 mRNA expression has been reported (Fan et aI., 1995) . Microglial IL-I a expression has been observed in human head injury (Griffin et aI., 1994) . Interleukin-13 mRNA expression has been shown to increase after transient brain ischemia in the rat (Minami et aI., 1992; Yabuuchi et aI., 1994) . The exac erbation of ischemic brain injury caused by exogenous IL-113 administered into the brain has been observed (Yamasaki et aI., 1995; Loddick and Rothwell, 1996) . A rapid (3 to 6 hours after ischemia) increase in IL-113 mRNA after MCAO peaked at 12 hours but returned to basal values at 5 days (Liu et aI., 1993) . Early IL-113 expression after focal stroke has also been shown using in situ hybridization (B uttini et aI., 1994) . The recent development of tools such as specific antibodies to rat IL-ll3 has permitted the identification (by immunohisto chemistry) of IL-113 peptide in cerebral vessels, microg lia and macrophages after focal stroke (Davies et aI., 1999; Zhang et aI., 1998b) .
Interleukin-l receptor antagonist (IL-lra), a 23 to 25 Kda glycosylated protein, is a naturally occurring in hibitor of IL-l activity that competes with IL-I for occupancy of IL-I RI without inducing a signal of its own. Interleukin-l receptor antagonist is produced by many different cellular sources including monocytes/ macrophages, endothelial cells, fibroblasts, neurons, and glial cells (Dinarello, 1996) . The expression of IL-l ra and IL-l R mRNA after focal stroke was also reported (Wang et aI., 1997) . The level of IL-la mRNA was markedly increased in the ischemic cortex at 6 hours, then reached a significantly elevated level from 12 hours to 5 days after MCAO. The presence of IL-lra in the normal brain and the upregulation of IL-lra mRNA after ischemic injury suggest that IL-lra may serve as a de fense system to attenuate the IL-l-mediated brain injury. It is interesting to observe that the temporal induction profile of IL-l ra after MCAO virtually parallels that of IL-113 as shown previously (Liu et aI., 1993a) that IL-lra mRNA exhibited prolonged elevation beyond that of IL-II3. Thus, the balance between the levels of IL-113 and IL-lra expressed after ischemia may be more critical to the degree of tissue injury than IL-l levels per se.
The mediators responsible for IL-lra induction after focal stroke are not known. However, previous studies indicate that some cytokines such as IL-l, TNF, IL-6, and transforming growth factor-13 are inducers of IL-lra (Dinarello, 1996) . Ischemia-induced expression of IL Ira mRNA could originate from monocytes/macro phages, endothelial cells, fibroblasts, neurons, and glial cells as observed previously under normal conditions (Dinarello, 1996) . The same cellular sources may be re sponsible for IL-ll3 and IL-lra production based on the close temporal, and perhaps functional coupling of these two genes after focal stroke.
CHANGES IN GENE EXPRESSION
As pointed out previously, focal ischemia is a very powerful stimulus to elicit genomic responses in the brain in the form of multiple gene expression. Tumor necrosis factor-a or IL-113 certainly are not the only in flammatory genes that are expressed in focal cerebral ischemia. Focal ischemia is a powerful stimulus that re sults in comprehensive genomic reformation of the brain. ous pro-inflammatory genes are up-regulated. Transcrip tion factors (immediate early genes are the first "wave" as shown by c-fos and others (c-jun, zif268, lun-B), but their expression is transient (Hsu et aI., 1993; Nowak et aI., 1990; Demura et aI., 1991; Wang et aI., 1995c; Welsh et aI., 1992) . A second wave consists of the heat shock proteins. Heat shock protein mRNA is usually ex pressed within 1 to 2 hours and then down-regulated by 1 to 2 days (Nowak et aI., 1990; Welsh et aI., 1992) .
Of great interest is the third wave (shaded in Fig. 4 ) that is largely comprised of increased cytokine gene ex pression as described earlier for TNF-a and IL-1 fj (Liu et aI., 1993a (Liu et aI., , 1994 Wang et aI., 1994b) , and including IL-6 (Wang et aI., 1995c) and IL-l ra (Wang et aI., 1997) . Chemokines such as IL-8 (Liu et aI., 1993a) , IP-10 (Wang et aI., 1998b) , and MCP-l (Wang et aI., 1995b; Kim et aI. , 1995) are also increased, and are likely to play a role in neutrophil and mononuclear cell infiltration. The presence of recruited leukocytes at the site of inflammation is critically dependent on the coor dinated expression of adhesion molecules (ligands and receptors) on inflammatory cells and the activated cap illary endothelium, respectively. These timed responses facilitate the efficient "docking" of activated immune cells to their respective receptors which is the primary step in the process of transendothelial migration and dia pedesis. Some of the candidate molecules include ICAM-l, ELAM-l, and P-selectin on the endothelial side, and CDll/CD 18, MAC-I, and LFA-l on the leu kocyte side (Beerhuizen and Van Furth, 1993; Granger and Kvietys, 1993) . After MCAO in rats, ICAM-l (Wang et aI., 1994) and ELAM-1 (Wang et aI., 1995) mRNA expression is increased within 1 to 3 hours. ICAM -I protein was localized to the capillary endothe lium in the infarcted cortex. After stroke in baboons (Okada et aI., 1994) , P-selectin and ICAM-l were shown to be up-regulated on the endothelium of postcapillary microvessels in the ischemic penumbra. The third wave also includes increased expression of the endothelial cell adhesion molecules such as ICAM-I, ELAM-l, and P selectin (Wang et aI., 1994 (Wang et aI., , 1995 Okada et aI., 1994; Zhang et aI., 1995 Zhang et aI., , 1996 Zhang et aI., , 1998a that are important in establishing endothelial adhesion to the leukocyte before infiltration. In addition, growth factors (Hsu et aI., 1993) (e.g., nerve growth factor, brain-derived nerve growth factor) that might be expected to play neuroprotective role(s) after stroke, and the tumor suppressor gene p53 (Li et aI., 1994 ) also increase in this time frame. This inflammatory wave is believed to play a key role in leukocyte infiltration (initially neutrophils; PMN, that are followed by monocytes/macrophages; Mono/M0 as indicated in Fig. 4 (Clark et aI., 1993 (Clark et aI., , 1994 Barone et al., 1991 Barone et al., , 1992b Barone et al., , 1995 . The third wave commences about one hour after stroke, peaks at about 12 hours, and subsides 2 to 5 days later. In this report, it is noteworthy that sensitivity of detection methods play an important role in defining these time frames; upon improved meth odology, it is possible that earlier transcriptional event might be monitored.
A fourth wave of new gene expression may well be associated with the inflammatory reaction to ischemia. This fourth wave includes proteolytic enzymes (metallo proteinases) implicated in remodeling of the extracellular matrix (Rosenberg et aI., 1996; Romanic et aI., 1998) , and their endogenous protease inhibitors, TMPI, (Wang et a!., 1998) , after focal stroke. The expression of these genes in stroke appears to be related to the influx of inflammatory cells and is associated with secondary brain injury and repair processes after stroke. The fifth wave of de novo transcription includes mediators such as transforming growth factor-fj (Wang et aI., 1995) and osteopontin (Wang et aI., 1998; Ellison et aI., 1998) which appear to be important in tissue remodeling, including formation of a new barrier to protect the nor mal, viable brain tissue. The relationship of the diverse gene expression to the progression of brain injury and the healing process (including plasticity that enables re covery of function long term after stroke) is depicted in Fig. 5 .
BRAIN INFLAMMATION: A DUAL-EDGED SWORD
The direct injection of minute amounts of TNF-a into the brain results in leukocyte adhesion to microvessel endothelium and infiltration into the tissue; however, no direct neurotoxicity to neurons at the site of injection was reported (Liu et aI., 1994) . Others have also shown that TNF-a is not directly toxic to neurons (Garcia et aI., 1992; Piani et aI., 1992) and some investigators even suggest a protective effect of TNF-a on neurons (Barger et aI., 1995; Cheng et a!., 1994; Schwartz et aI., 1991) . The dual capacity of TNF-a to convey injurious or ben eficial effects have been emphasized previously (Tracey and Cerami, 1994) . The capacity of TNF-a to provide beneficial effects in brain injury is inferred from studies with TNF-receptor knock-out mice (p55 and p75 knock out) which display increased sensitivity to brain ischemia (Bruce et aI., 1996; Rothwell and Luheshi, 1996) and the capacity of TNF and IL-l to elicit states of ischemic tolerance on repeated administration (Ohtsuki et aI., 1996; Nawashiro et aI., 1997b) . A later expression of TNF-a in macrophages involved in resolution of isch emic brain injury has been described (Clark et aI., 1993 (Clark et aI., , 1994 Liu et aI., 1994) . However, the data to date show that augmenting the acute effects of TNF-a and IL-IB is not protective (and in fact increase ischemic injury) and that blocking the acute surges in TNF-a and IL-IB that occur after focal stroke is neuroprotective (see below). Figure 6 illustrates the relative timing of the dynamic changes that occur after stroke. This scheme suggests a progression of events through repair and remodeling and into neuronal plasticity and recovery of function (Jenkins and Merzenich, 1987; Li et aI., 1998a) . Note that brain inflammation spans across all these processes and can be expected to influence early injury and later postinjury repair processes. Postinjury plasticity and functional re covery has been shown to be activity-dependent and is influenced by training (Johansson and Grabowski, 1994) and facilitated by growth factors (Kawamata et aI., 1997). Although initial brain inflammation can contrib ute to the degree of brain damage after injury, anti inflammatory interventions to limit the degree of damage have been shown to interfere with nervous regeneration FIG. 6 . Schematic diagram depicting relative time sequence of the dynamic changes that occur after ischemic stroke. Of par ticular interest is the brain inflammation that occurs throughout all other phases of brain changes in response to initial ischemia! injury. Text describes the "yin/yang" involvement of brain inflam mation in exacerbation and evolution of initial ischemic injury, and in the repair and recovery of function of neuron tissue following injury. and recovery (Hirschberg et aI., 1994) . In addition, re cent data (Moalem et aI., 1999) indicate that activated T cells can protect neurons from secondary degeneration after central axonomy. Also, recruitment of activated macrophages in lesioned spinal cord was linked to re generation failure after injury in the CNS (Lazarov Spiegler et aI., 1998). Interleukin-1 has been associated with dopaminergic sprouting in denervated striatum (Ho and Blum, 1998) and increased neuronal TNF-a ob served during spinal cord recovery in experimental al lergic encephalomyelitis also suggests additional repara tive recovery roles for TNF-a in the CNS (Villarroya et aI., 1997) . Better regeneration occurs in the CNS asso ciated with more marked inflammation (Guest et aI., 1997) and activated macrophage and microglia facilita tion of neuronal plasticity/recovery after injury is appar ently associated with secretion of neurotrophic factors from the macrophages (Batchelor et aI., 1999). There fore, the inflammation that does occur in response to injury in the CNS appears to serve multiple purposes. While certain strategies may be required to intervene early in brain inflammation to reduce injury and neuro degeneration, other intervention may be necessary to fa cilitate repair and recovery of regeneration processes af ter CNS injury (Dopp and deVillis, 1998; Lazarov Spiegler et aI., 1998) . Clearly, more must be learned about these complex interactions. In addition, timing of specific interventions may be critical to development of significant neuroprotective anti-inflammatory therapy. A recent, novel anti-inflammatory cytokine experimental approach has shown the neuroprotective effects of IL-lO administration in both stroke (Spera et aI., 1998) and neurotrauma (Knoblach and Faden, 1998) . These latter reports may suggest that certain anti-inflammatory modulatory cytokines may be of therapeutic potential in ischemic or traumatic brain injury. Matsuo et aI. (1994) have used the RP-3 monoclonal antibody that selectively depletes leukocytes in the rat (about 90% to 95%) and reported a dramatic reduction in both neutrophil accumulation in focal ischemic brain tis sue and infarct size (decreased by 45% to 50%). Al though some controversy exists (Hayward et aI., 1996) , other studies have verified these effects in various ex perimental models (Chen et aI., 1992; Jaing et aI., 1998; Dutka et aI., 1989; Shiga et aI., 199 1; Heinel et aI., 1994; Bowes et aI., 1995; Bednar et aI., 199 1; Vasthare et aI., 1990; Hartl et aI., 1996) . However, although these "depletion" experiments support the hypothesis that early inflammatory cell infiltration in stroke exacerbates ischemic injury, this strategy is unlikely to translate into clinical use.
ANTI· LEUKOCYTE STRATEGIES FOR NEUROPROTECTION
ANTI· ADHESION MOLECULE ANTAGONISTS FOR NEUROPROTECTION
Another attractive approach is the inhibition of endo thelial interactions with the leukocyte. Chen et aI. (1994) treated MCAO rats intravenously with an antibody against MAC-I, the leukocyte counterpart of ICAM-I binding and demonstrated reduction in infarct size by 45 % to 50% in a rat transient MCAO model. Zhang et aI. (1994b) used the intravenous administration of an anti ICAM-1 antibody to demonstrate a 40% reduction of infarct size in a similar model. Blocking adhesion mol ecules can also reduce apoptosis induced by focal isch emia (Chopp et aI., 1996) . Other studies verified these effects but also illustrated that these antibodies could not reduce infarct size when the ischemia was permanent (Chopp et aI., 1994; Jiang et aI., 1994; Bowes et aI., 1993; Clark et aI., 199 1; Zhang et aI., 1995) . However, the strategy may work if both leukocyte and endothelial adhesion proteins are blocked in permanent focal stroke. The combination of t-PA and anti-CD 18 provides sig nificantly improved outcome, and may increase the therapeutic time window in stroke (Zhang et aI., 1999) .
In a rabbit embolic model of stroke, anti-ICAM -1 anti body was shown to increase the amount of clot necessary to produce permanent damage (Bowes et aI., 1993) . In addition, in a baboon model of transient focal ischemia anti-CD 18 monoclonal antibody administered 25 min utes before reperfusion led to an increase in reflow in microvessels of various sizes (Mori et aI., 1992) . How ever, in contrast to the demonstrated anti-ischemic effect of anti-adhesion molecules in animal models, the recent failure of the murine anti-ICAM monoclonal antibody (enlimomab) in human stroke (DeGraba, 1998) , and its ability to activate human neutrophils (Vuorte et aI., 1999) show the difficulties in extrapolating encouraging data derived from animal models to clinical reality.
NEUROPROTECTION BY CYTOKINE INHIBITION SUPPORTS ANTI·INFLAMMATORY APPROACH
An alternate possibility to modulate inflammation is to aim directly for cytokine and chemokine suppressive agents. While proof for a role of TNF-cx and IL-113 in ischemia brain damage has not been definitively estab lished, the availability of selective and potent antagonists of cytokine production may aid in reaching this goal. Many studies have shown the protective effects ofIL-I ra in brain injury. Thus, intracerebroventricular administra tion of recombinant IL-lra produced a marked reduction in brain damage induced by focal stroke (Reiton et aI., 1996; Rothwell and Relton, 1993; Loddick and Rothwell, 1996) , brain hypoxia-ischemia (Martin et aI., 1995) , or fluid percussion injury in the rat (Toulmond and Rothwell, 1995) . This neuronal protective effect of IL-I ra in focal stroke was further supported by a recent study using an adenoviral vector that overexpressed IL-1 ra in the brain (Betz et aI., 1995) . The excess of IL-l ra significantly reduced infarct size after focal stroke. While such modes of IL-lra delivery are impractical in clinical terms, the studies point out a potential therapeu tic remedy if delivery of IL-\ ra can be achieved in a timely manner. In addition, IL-lra expression increases after ischemic preconditioning in a manner that parallels the development of brain ischemic tolerance (Barone et aI., 1998) . Of interest is data showing that peripheral administration of IL-I ra reduces brain injury (Relton et aI., 1996) , suggesting a potential use of IL-\ ra as a neu roprotective agent in human stroke and/or neurotrauma. Likewise, several studies have shown that blocking TNF-cx results in improved outcome in brain trauma and stroke. Pentoxifyline (a methylxanthine that reduces TNF-cx production at the transcriptional level) or soluble TNF receptor I (which acts by competing with TNF-cx at the receptor) improves neurologic outcome, reduces the disruption of the blood-brain barrier, and protects hippo campal cells from delayed cell death after closed head injury in the rat (Shohami et aI., 1996) . In rat focal isch emia, an anti-TNF-cx monoclonal antibody and the soluble TNF receptor I were neuroprotective (Barone et aI., 1997a). In the latter studies, TNF-cx was blocked by repeated intracerebroventricular administrations before and during focal stroke which significantly reduced in farct size. In murine focal stroke, topical application of soluble TNF receptor I on the brain surface significantly reduced ischemic brain injury (Nawashiro et aI., 1997a) . In addition, in another study evaluating TNF blockade on focal stroke in hypertensive rats, soluble TNF receptor I administered intravenously, before or after MCAO, sig nificantly reduced the impairment in ischemic cortex mi crovascular perfusion and the degree of cortical infarc tion, strongly suggesting an inflammatory/vascular mechanism for TNF-a in focal stroke (Dawson et a!., 1996) .
The detrimental effects of TNF-a and its role as a mediator of focal ischemia may involve several mecha nisms. For example, TNF-a increases blood-brain barrier permeability and produces pial artery constriction that can contribute to focal ischemic brain injury. Further more, a direct toxic effect of TNF-a on the capillaries was also noted (Goldblum and Sun, 1990; Beutler and Cerami, 1987) . Also, by stimulating the production of matrix-degradating metalloproteinase (gelatinase B) (Kim et a!., 1995; Rosenberg et a!., 1996; Romanic et aI., 1998; Rosenberg et a!., 1995), TNF-a may further exac erbate capillary integrity. Tumor necrosis factor-a also causes damage to myelin and oligodendrocytes (Robbins et aI., 1987; Selmaj and Raine, 1988) and increases as trocytic proliferation thus potentially contributing to de myelination and reactive gliosis. In addition, TNF-a ac tivates the endothelium for leukocyte adherence and pro coagulation activity (i.e., increased tissue factor, von Willebrand factor, and platelet activating factor) that can exacerbate jschemic damage (pober and Cotran, 1990) . Indeed, increased TNF-a in the brain and blood in re sponse to lipopolysaccharide seems to contribute to in creased stroke sensitivity/risk in hypertensive rats (Feu erstein et a!., 1998; Siren et aI., 1992; Hallenbeck et a!., 1988; Barone et aI., 1992) . Tumor necrosis factor-a ac tivates neutrophils (Shalaby et aI., 1985) increases leu kocyte-endothelial cell adhesion molecule expression (Balasingam et aI., 1994) , leukocyte adherence to blood vessels, and subsequent infiltration into the brain (for review see Feuerstein et a!., 1998).
Interference with either IL-1 13 or TNF-a has now been shown repeatedly to result in reduced deficits in focal stroke and head trauma models. The evaluation of addi tional potent and specific anti-cytokine therapeutics in proper models of brain injury is clearly warranted. Much evidence has accumulated that indicates TNF-a produc tion is regulated at both transcriptional and translational levels (Tracey and Cerami, 1993) . Thus, TNF-a mRNA synthesis inhibitors such as rolipram (Semmler et a!., 1993) , a phosphodiesterase IV inhibitor, could be of ben efit in the treatment of brain inflammation. In addition, selective inhibition of this phosphodiesterase a predomi nant isoform in cerebral vessels, mediates significant va sorelaxation that can also improve outcome in stroke (Willette et a!., 1997) . Other novel classes of drugs in clude highly specific protein kinase C inhibitors such as calphostin C (Kobayashi et a!., 1990), which has been shown to potently inhibit lipopolysaccharide endotoxin stimulated TNF-a production from human monocytes in vitro (Prabhakar et aI., 1993) as well as lipopolysaccha ride endotoxin and viral stimulated TNF-a production in astrocytic cell lines (Lieberman et aI., 1989 (Lieberman et aI., , 1992 . In terestingly, protein kinase C also serves as a "focal point" in the regulation of production of IL-113 (Gorospe et aI., 1993) and endothelial cell-derived adhesion mol ecules (pober and Cotran, 1990) . However, because of the ubiquitous nature of protein kinase C, nonselective inhibitors may result in toxic consequences. However, the finding that liposome-entrapped staurosporine greatly enhanced survival in a rat model of endotoxemia possibly related to the suppression of serum TNF-a levels (Tschaikowsky and Brain, 1994) , supports the feasibility of such a pharmacologic paradigm to prevent brain in flammation. Further advances in this approach will be derived from the development of isozyme-specific pro tein kinase C inhibitors (Wilkinson and Hallam, 1994) . The utility of blocking inflammatory cytokines in con junction with thrombolysis using tissue plasminogen ac tivator has been discussed recently (Garcia et aI., 1997). Figure 7 illustrates the general features of the mitogen activated protein kinase (MAPK) family. Many neuro trophins/growth factors bind to Trk receptors and signal through Ras MAPK pathway via ERKlMAPK (for re view see Skaper and Walsh, 1998) . . General features of the mitogen-activated protein kinase (MAPK) family. Stimuli, typically acting at the cell surface, provide second messenger signaling via a cascade of protein phosphory lations to result in a response, typically at the level of protein transcription or translation. Of particular interest is the stress ac tivated MAP kinase pathway involving p38 MAPK which is selec tively inhibited by cytokine suppressive anti-inflammatory drugs (CSAIDs). p38 MAPK was originally referred to as the CSAID Binding Protein; CSBP). CSAIDs inhibit the production of the inflammatory cytokines tumor necrosis factor (TNF) and interleu kin (IL)-1. CSAIDs/p38 MAPK inhibitors act after p38 MAPK ac tivation (via its phosphorylation from upstream kinases) to pre vent p38 activation/phosphorylation of downstream kinases (e.g., MAPKAPK2). Thus, the cellular inflammatory cytokine production and apoptosis in response to various cellular stressors (e.g., isch emia or trauma) can be blocked. See text for details.
MITOGEN-ACTIVATED PROTEIN KINASES: A NOVEL APPROACH TO CYTOKINE SUPPRESSION
tein kinases (e.g., p38 and JNK, Fig . 7 ) play an important role in transducing stress-related signals by a cascade of phosphorylation of intracellular kinases and transcription factors (Robinson and Cobb, 1997 ) that regulate cell sur vival ' apoptosis, and inflammatory cytokine production (Kummer et aI., 1997; Lee et aI., 1994; Lee and Young, 1996; Xia et aI., 1995) . Sustained activation of JNK and p38 MAPK inhibitors promote (in vitro) survival of sen sory, sympathetic, ciliary, dorsal root ganglia, and motor neurons (Horstmann et aI., 1998; Skaper and Walsh, 1998) . In PC 12 cells, withdrawal of nerve growth factor causes apoptosis that is preceded by decreased ERK and increased JNKJp38 activity (Xia et aI., 1995) , suggesting a balance between ERK and stress-activated MAPKs un der some conditions to mediate cell survival. Apoptosis of PC 12 cells is associated with p38 activation and is reduced by inhibiting p38IMAPK activity (Kummer et aI., 1997; Xia et aI., 1995) . In addition, insulin promotes survival of cultured forebrain neurons concomitant with inhibition of p3 8 (Heidenreich and Kummer, 1996) , and p38IMAPK activation has been shown to be involved in glutamate toxicity-induced neuronal apoptosis (Ka wasaki et aI., 1997). In global forebrain ischemia, p38J MAPK activation has been identified in microglial cells adjacent to dying, vulnerable neurons (Barone et aI ., 1999; Walton et al., 1998) .
Recently, a new class of compounds, cytokine suppressive anti-inflammatory drugs, have been devel oped which are potent inhibitors of TNF-a and IL-l13 production (Young et aI., 1993 (Young et aI., , 1997 Lee et aI., 1993 Lee et aI., , 1994 Lee et aI., , 1996 Kassis and Prabhakar 1993; Kumar et aI., 1997) . Interestingly, these pyridinyl imidazole drugs have been shown to block translation of both TNF-a and IL-l13 by mechanisms independent of cAMP. Cytokine suppressive anti-inflammatory drugs block the ability of activated (phosphorylated) p38 to phosphorylate down stream kinases in the signaling cascade (e.g., cytokine suppressive anti-inflammatory drugs block the activation of MAPKAP-K2&3; see Fig. 7 ) (Kumar et aI., 1997) . Not only do cytokine suppressive anti-inflammatory drugJp3 8 MAPK inhibitors block the production of IL-113 and TNF-a, but they also block the expression of several inflammatory proteins, including inducible nitric oxide synthase (Badger et aI., 1998; Bhat et aI., 1998) and the chemokine IL-8 (Lee et aI., 1993) .
Taken together, several aspects of the inflammatory cascade might be targeted by the inhibition of p3 8J MAPK . Certainly, apoptosis contributes significantly to ischemic stroke injury and its outcome (Li et aI., 1998b; MacManus and Linnik, 1997; Morrison et aI., 1998) . In addition, the convergence of inflammatory cytokines and apoptotic pathways may result in reduced delayed neu ronal death. (Hara et aI., 1997; Sidotidefraisse et aI ., 1998) . Thus, targeting p38JMAPK might be expected to provide an opportunity for intervention not only in early cytokine production but also to block delayed neuronal death by apoptosis. Very recently, we have identified significant neuroprotection by selectively inhibiting sig nificant activation of p38 (Irving et aI., 1999) and in focal brain ischemia, in vivo (Barone et aI., 1999) .
SUMMARY
Throughout the last decade, a well-defined inflamma tory reaction to diverse insults to the brain has been defined. Many aspects of this in situ and de novo inflam matory response has been enabled by application of mo lecular biologic techniques including PCR, cDNA library strategies and genetics in conjunction with highly spe cific probes (antibodies, DNA/RNA) that illustrate the comprehensive inflammatory capacity of the brain. Tu mor necrosis factor-a and IL-I13 emerge as reasonable candidates for pharmacologic manipulation in view of modulating the inflammatory response induced by stroke. The emerging understanding of the discrete mo lecular pathways in cytokines synthesis and their signal ing mechanisms (e.g., p38JMAPK) already resulted in promising new opportunities for selective intervention in cytokine-mediated actions that are believed to contribute to histologic and functional outcomes of stroke and neu rotrauma. It is hoped that rapid development of these compounds for clinical trials in stroke will result in new therapeutics for this devastating disease. 
